Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

Launched by SHIN POONG PHARMACEUTICAL CO. LTD. · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new combination treatment called SPC1001 for patients with essential hypertension, which is high blood pressure that isn't caused by another condition. The treatment includes three medications: candesartan, amlodipine, and indapamide, taken together in one pill. The goal is to see if this fixed-dose combination is safe and more effective than taking two of these medications separately over an 8-week period.

To participate, you should be between 19 and 75 years old and have specific blood pressure readings that meet the study's criteria. Before starting the trial, participants will go through a screening process, and those who qualify will first take a placebo (a pill with no active medication) for two weeks while also making some lifestyle changes to help manage their blood pressure. This trial is currently recruiting participants, and it's important to note that people with very high blood pressure will not be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
• Exclusion Criteria:
• • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.